Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Schnitzler syndrome
2010-023603-10Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Schnitzler syndrome, sponsored by UZ Leuven. Primary endpoints: Clinical efficacy (composite) and Complete clinical response at Day 7. Started Dec 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on 2010-023603-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023603-10.